Trials / Completed
CompletedNCT05914688
A Study to Compare Two Formulations of LY3209590 in Healthy Participants
A Bioequivalence Study of Subcutaneous Injections of LY3209590 in Two Formulations in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to compare the two formulations of LY3209590 in healthy participants. Study participants will be administered each formulation at separate study visits. Blood samples will be taken to compare how the body handles study drugs. The information about any adverse effects experienced will be collected and the tolerability of LY3209590 will also be evaluated. Screening is required within 28 days prior to enrolment. For each participant, the total duration of the clinical trial will be about 184 days including screening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3209590 (Formulation 1) | Administered SC. |
| DRUG | LY3209590 (Formulation 2) | Administered SC. |
Timeline
- Start date
- 2023-06-26
- Primary completion
- 2024-01-18
- Completion
- 2024-01-18
- First posted
- 2023-06-22
- Last updated
- 2024-04-23
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT05914688. Inclusion in this directory is not an endorsement.